Abliva AB (publ) (NEVPF)
USD 0.04
(0.0%)
USD 0.04
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.65 Million USD | -11.25% |
| 2022 | 1.86 Million USD | -2.53% |
| 2021 | 1.91 Million USD | 52.65% |
| 2020 | 1.25 Million USD | -43.27% |
| 2019 | 2.21 Million USD | 7.14% |
| 2018 | 2.06 Million SEK | 18.49% |
| 2017 | 1.74 Million SEK | 27.47% |
| 2016 | 1.36 Million SEK | -42.83% |
| 2015 | 2.38 Million SEK | -89.8% |
| 2014 | 23.42 Million SEK | 61.19% |
| 2013 | 14.53 Million SEK | 71.74% |
| 2012 | 8.46 Million SEK | 410.74% |
| 2011 | 1.65 Million SEK | 69.52% |
| 2010 | 977.43 Thousand SEK | -12.86% |
| 2009 | 1.12 Million SEK | 75.07% |
| 2008 | 640.74 Thousand SEK | -47.48% |
| 2007 | 1.22 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 961.92 Thousand USD | -38.63% |
| 2024 Q2 | 777.02 Thousand USD | -19.65% |
| 2023 Q2 | 1.25 Million USD | 71.7% |
| 2023 Q4 | 1.65 Million USD | 37.03% |
| 2023 FY | 1.65 Million USD | -11.25% |
| 2023 Q3 | 1.2 Million USD | -3.96% |
| 2023 Q1 | 732.96 Thousand USD | -60.72% |
| 2022 Q1 | 4.41 Million SEK | 130.58% |
| 2022 FY | 1.86 Million USD | -2.53% |
| 2022 Q4 | 1.86 Million USD | -4.76% |
| 2022 Q3 | 1.95 Million USD | 6.78% |
| 2022 Q2 | 1.83 Million SEK | -58.44% |
| 2021 Q1 | 2.08 Million SEK | -79.8% |
| 2021 Q2 | 2.16 Million SEK | 4.14% |
| 2021 Q3 | 2.49 Million SEK | 15.23% |
| 2021 Q4 | 1.91 Million SEK | -23.34% |
| 2021 FY | 1.91 Million USD | 52.65% |
| 2020 Q3 | 9.04 Million SEK | -41.07% |
| 2020 Q4 | 10.3 Million SEK | 13.87% |
| 2020 FY | 1.25 Million USD | -43.27% |
| 2020 Q1 | 8.63 Million SEK | -58.28% |
| 2020 Q2 | 15.35 Million SEK | 77.8% |
| 2019 Q2 | 19.55 Million SEK | 45.45% |
| 2019 FY | 2.21 Million USD | 7.14% |
| 2019 Q4 | 20.69 Million SEK | 35.52% |
| 2019 Q3 | 15.27 Million SEK | -21.92% |
| 2019 Q1 | 13.44 Million SEK | -26.5% |
| 2018 Q1 | 15.44 Million SEK | 8.32% |
| 2018 Q4 | 18.29 Million SEK | 38.8% |
| 2018 Q3 | 13.18 Million SEK | -1.3% |
| 2018 Q2 | 13.35 Million SEK | -13.53% |
| 2018 FY | 2.06 Million SEK | 18.49% |
| 2017 Q2 | 10.17 Million SEK | 27.89% |
| 2017 Q3 | 7.91 Million SEK | -22.17% |
| 2017 Q4 | 14.25 Million SEK | 80.15% |
| 2017 FY | 1.74 Million SEK | 27.47% |
| 2017 Q1 | 7.95 Million SEK | -35.94% |
| 2016 Q1 | 19.9 Million SEK | -1.19% |
| 2016 Q4 | 12.41 Million SEK | 17.18% |
| 2016 Q3 | 10.59 Million SEK | 3.04% |
| 2016 FY | 1.36 Million SEK | -42.83% |
| 2016 Q2 | 10.28 Million SEK | -48.37% |
| 2015 Q4 | 20.14 Million SEK | -30.87% |
| 2015 Q2 | 21.29 Million SEK | -11.01% |
| 2015 FY | 2.38 Million SEK | -89.8% |
| 2015 Q1 | 23.92 Million SEK | 2.13% |
| 2015 Q3 | 29.14 Million SEK | 36.88% |
| 2014 Q3 | 9.69 Million SEK | 7.54% |
| 2014 FY | 23.42 Million SEK | 61.19% |
| 2014 Q4 | 23.42 Million SEK | 141.64% |
| 2014 Q2 | 9.01 Million SEK | -37.73% |
| 2014 Q1 | 14.47 Million SEK | -0.39% |
| 2013 Q2 | 7.51 Million SEK | -5.77% |
| 2013 Q3 | 8.82 Million SEK | 17.5% |
| 2013 Q4 | 14.53 Million SEK | 64.71% |
| 2013 FY | 14.53 Million SEK | 71.74% |
| 2013 Q1 | 7.97 Million SEK | -5.83% |
| 2012 Q4 | 8.46 Million SEK | 79.11% |
| 2012 Q1 | 3.29 Million SEK | 98.61% |
| 2012 Q2 | 6.36 Million SEK | 93.44% |
| 2012 FY | 8.46 Million SEK | 410.74% |
| 2012 Q3 | 4.72 Million SEK | -25.78% |
| 2011 FY | 1.65 Million SEK | 69.52% |
| 2011 Q1 | 742.1 Thousand SEK | -24.08% |
| 2011 Q2 | 2.69 Million SEK | 263.32% |
| 2011 Q3 | 1.15 Million SEK | -57.32% |
| 2011 Q4 | 1.65 Million SEK | 43.98% |
| 2010 Q4 | 977.43 Thousand SEK | 35.8% |
| 2010 Q3 | 719.76 Thousand SEK | -62.45% |
| 2010 Q1 | 6.44 Million SEK | 474.68% |
| 2010 Q2 | 1.91 Million SEK | -70.26% |
| 2010 FY | 977.43 Thousand SEK | -12.86% |
| 2009 Q4 | 1.12 Million SEK | 0.0% |
| 2009 FY | 1.12 Million SEK | 75.07% |
| 2008 FY | 640.74 Thousand SEK | -47.48% |
| 2007 FY | 1.22 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 96.893% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 82.715% |
| SQZ Biotechnologies Company | 50.03 Million USD | 96.69% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 97.715% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 97.193% |
| Mesoblast Limited | 188.44 Million USD | 99.121% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 56.996% |
| Genus plc | 485 Million USD | 99.658% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 71.652% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 34.179% |
| Marizyme, Inc. | 26.67 Million USD | 93.791% |
| ContraFect Corporation | 32.53 Million USD | 94.909% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 56.414% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 16.405% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 56.728% |
| Intellipharmaceutics International Inc. | 12 Million USD | 86.208% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 85.938% |
| MultiCell Technologies, Inc. | 1617.67 USD | -102287.013% |
| Accustem Sciences Inc. | 1.07 Million USD | -53.468% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 97.861% |
| EV Biologics, Inc. | 2.11 Million USD | 21.691% |
| Q BioMed Inc. | 8.13 Million USD | 79.635% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 98.003% |
| Neon Bloom, Inc. | 1.22 Million USD | -35.073% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 67.814% |
| Biomind Labs Inc. | 1.49 Million USD | -10.521% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 99.321% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 91.0% |
| Skye Bioscience, Inc. | 14.07 Million USD | 88.23% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 17.603% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -1065.617% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 82.503% |
| IMV Inc. | 37.93 Million USD | 95.634% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -723.547% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 71.174% |
| GB Sciences, Inc. | 5.41 Million USD | 69.427% |
| Alpha Cognition Inc. | 7.16 Million USD | 76.883% |
| HST Global, Inc. | 593.59 Thousand USD | -179.027% |
| CSL Limited | 18.62 Billion USD | 99.991% |
| Halberd Corporation | 728.71 Thousand USD | -127.287% |
| Enzolytics Inc. | 365.26 Million USD | 99.547% |
| Resverlogix Corp. | 67.39 Million USD | 97.542% |
| Affymax, Inc. | 8.87 Million USD | 81.329% |
| SYBLEU INC | 681.41 Thousand USD | -143.066% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -97.475% |
| argenx SE | 444.95 Million USD | 99.628% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 97.789% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 3.367% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 86.085% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 54.81% |
| AVAX Technologies, Inc. | 3.99 Million USD | 58.528% |
| Zenith Capital Corp. | 27.56 Thousand USD | -5907.777% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.875% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -594.011% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 55.647% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -143.273% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 98.605% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 81.683% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -2374.688% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -15.512% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 96.705% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 38.919% |
| BioStem Technologies, Inc. | 15.9 Million USD | 89.586% |
| ONE Bio Corp. | 27.49 Million USD | 93.976% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -256.421% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -5937.561% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -31.535% |
| Agentix Corp. | 2.51 Million USD | 34.027% |
| LadRx Corporation | 2.2 Million USD | 24.732% |
| Cell Source, Inc. | 15.8 Million USD | 89.522% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -3605.665% |
| Regen BioPharma, Inc. | 5.45 Million USD | 69.652% |
| Regen BioPharma, Inc. | 5.45 Million USD | 69.652% |
| NovAccess Global Inc. | 7.86 Million USD | 78.93% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 93.307% |
| Itoco Inc. | 1.65 Million USD | -0.19% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 19.267% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 72.619% |
| Kadimastem Ltd | 3.5 Million USD | 52.743% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -292.887% |
| CytoDyn Inc. | 127.89 Million USD | 98.705% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -3862.497% |
| Mobile Lads Corp. | 1.31 Million USD | -26.097% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -5.74% |
| Qrons Inc. | 1.48 Million USD | -11.256% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 85.005% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -104.784% |
| Rebus Holdings, Inc. | 5.24 Million USD | 68.404% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 72.856% |
| International Stem Cell Corporation | 5.27 Million USD | 68.613% |
| Bioxytran, Inc. | 3.24 Million USD | 49.03% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -164.663% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 64.127% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 95.96% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 92.561% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 18.224% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 69.765% |
| Neutra Corp. | 973.52 Thousand USD | -70.132% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 94.292% |
| PureTech Health plc | 125.58 Million USD | 98.681% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 55.916% |
| IXICO plc | 1.9 Million USD | 12.841% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 91.932% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.397% |
| CSL Limited | 18.62 Billion USD | 99.991% |
| Cellectis S.A. | 249.36 Million USD | 99.336% |